Pascal Pierre
Université catholique de Louvain
6 Papers
51 Citations
Pascal Pierre is an academic researcher from Université catholique de Louvain. The author has contributed to research in topics: Biology & Receptor tyrosine kinase. The author has an hindex of 6, co-authored 6 publications.
Chat about Author
Papers
The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation.
Federica Toffalini,Anders Kallin,Peter Vandenberghe,Pascal Pierre,Lucienne Michaux,Jan Cools,Jean-Baptiste Demoulin +6 more
TL;DR: In this paper, the degradation of hybrid and wild-type receptor tyrosine kinases was compared in patients with chronic myeloid neoplasms associated with eosinophilia.
46
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
Jo-Anne van der Krogt,Marlies Vanden Bempt,Julio Finalet Ferreiro,Nicole Mentens,Kris Jacobs,Ursula Pluys,Kathleen Doms,Ellen Geerdens,Anne Uyttebroeck,Pascal Pierre,Lucienne Michaux,Timothy Devos,Peter Vandenberghe,Thomas Tousseyn,Jan Cools,Iwona Wlodarska +15 more
TL;DR: Lymphomas driven by the variant ATIC-ALK fusion (and likely by RNF213-ALK and TPM3-ALK), but not the classic NPM1-ALK, require an increased dosage of the ALK hybrid gene to compensate for the relatively low and insufficient expression and signaling properties of the chimeric gene.
34
The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome
Marie-Christiane Vekemans,H Lemmens,Michel Delforge,Chantal Doyen,Pascal Pierre,Hilde Demuynck,G. Bries,Jan Lemmens,Peter Meeus,Nicole Straetmans,Deborah Bauwens,Sébastien Vidrequin,Katrina Rack,Peter Vandenberghe,Iwona Wlodarska,Lucienne Michaux +15 more
TL;DR: It is proposed that prophylactic, parenteral thiamine should be administered to all patients receiving second-line anti-emetic therapy during high-dose chemotherapy for CNS malignancy.
9
Myelofibrosis patients in Belgium: disease characteristics.
Timothy Devos,Pierre Zachee,D. Bron,Lucien Noens,J Van Droogenbroeck,Philippe Mineur,Yves Beguin,Zwi N. Berneman,Fleur Samantha Benghiat,Alain Kentos,Christian Chatelain,Hilde Demuynck,Jan Lemmens,K. Van Eygen,Koen Theunissen,Fabienne Trullemans,Pascal Pierre,Wim Pluymers,Laurent Knoops +18 more
TL;DR: Insight is provided into the characteristics of the Belgian myelofibrosis population and it is suggested that a large proportion of these patients could stand to benefit from the therapies currently under development.
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
Michel Delforge,Dominik Selleslag,Yves Beguin,Agnes Triffet,Philippe Mineur,Koen Theunissen,Carlos Graux,Fabienne Trullemans,D Boulet,Koen Van Eygen,Lucien Noens,Steven Van Steenweghen,Jan Lemmens,Pascal Pierre,Randal D’hondt,Augustin Ferrant,Dries Deeren,Ann Van de Velde,Wim Wynendaele,Marc André,Robrecht De Bock,André Efira,Dimitri Breems,Anne Deweweire,Kurt Geldhof,Wim Pluymers,Amanda T. Harrington,Karen MacDonald,Ivo Abraham,Christophe Ravoet +29 more
TL;DR: Six or more months of adequate ICT is associated with markedly better overall survival, suggesting a possible survival benefit of ICT in transfusion-dependent patients with lower-risk MDS.